OrbiMed Portfolio holdings
OrbiMed is an investment manager focused exclusively on healthcare, running public equity, private equity and private credit and royalty funds. The firm traces its origins to 1989, when Viren Mehta and Samuel Isaly, both pharmaceutical analysts at the bank S.G Warburg, set up the research and money-management firm Mehta & Isaly; in 1998 it split in two, with Isaly forming OrbiMed and Mehta forming Mehta Partners. Its public equity side covers long/short funds built around corporate events as well as closed-end investment trusts, and OrbiMed launched its first dedicated venture capital fund in 2000 and its first royalty and credit fund in 2011. Carl Gordon, Carter Neild and Geoffrey Hsu form the committee that leads the firm, which is owned and controlled by eight members.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
+$201M |
| 2 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$91.6M |
| 3 |
uniQure
QURE
|
+$57.2M |
| 4 |
Natera
NTRA
|
+$47.4M |
| 5 |
ATNX
Athenex, Inc. Common Stock
ATNX
|
+$47.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CMTA
Clementia Pharmaceuticals Inc.
CMTA
|
+$272M |
| 2 |
Guardant Health
GH
|
+$118M |
| 3 |
Viatris
VTRS
|
+$77.1M |
| 4 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$64M |
| 5 |
Humana
HUM
|
+$55.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.94% |
| 2 | Miscellaneous | 1.85% |
| 3 | Financials | 1.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$16.5B
| $443M | 6.86% |
3,846,673
-124,000
| -3% | -$14.8M |
2015 Q1
17 quarters
|
|
|
TCDA
2
DELISTED
Tricida, Inc. Common Stock
TCDA
| $439M | 6.79% |
11,114,280
+225,000
| +2% | +$7.91M |
2018 Q2
4 quarters
|
|
3
Boston Scientific
BSX
$60.8B
| $290M | 4.49% |
6,752,500
+962,100
| +17% | +$37M |
2014 Q1
21 quarters
|
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $252M | 3.91% |
1,926,085
-31,115
| -2% | -$4.01M |
2013 Q2
24 quarters
|
|
5
Alector
ALEC
$247M
| $250M | 3.88% |
13,182,329
| – | – |
2019 Q1
1 quarter
|
|
6
Merck
MRK
$369B
| $216M | 3.34% |
2,693,465
| – | – |
2016 Q1
13 quarters
|
|
|
PRVL
7
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $182M | 2.83% |
+13,822,463
| New | +$201M |
2019 Q2
0 quarters
|
|
8
Vertex Pharmaceuticals
VRTX
$142B
| $178M | 2.76% |
973,300
+18,000
| +2% | +$3.15M |
2013 Q2
24 quarters
|
|
9
Neurocrine Biosciences
NBIX
$14.9B
| $155M | 2.4% |
1,833,200
| – | – |
2018 Q1
5 quarters
|
|
10
Iovance Biotherapeutics
IOVA
$3.84B
| $136M | 2.11% |
5,548,326
| – | – |
2015 Q1
17 quarters
|
|
11
Thermo Fisher Scientific
TMO
$258B
| $136M | 2.1% |
462,800
+15,500
| +3% | +$4.27M |
2013 Q2
24 quarters
|
|
12
Edwards Lifesciences
EW
$53B
| $132M | 2.05% |
2,145,000
| – | – |
2016 Q1
13 quarters
|
|
13
Sarepta Therapeutics
SRPT
$1.97B
| $126M | 1.95% |
828,400
| – | – |
2017 Q4
6 quarters
|
|
|
WMGI
14
DELISTED
Wright Medical Group Inc
WMGI
| $125M | 1.93% |
4,187,799
| – | – |
2014 Q3
19 quarters
|
|
15
Intuitive Surgical
ISRG
$153B
| $110M | 1.71% |
630,900
| – | – |
2013 Q4
22 quarters
|
|
|
TPTX
16
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $104M | 1.62% |
+2,567,550
| New | +$91.6M |
2019 Q2
0 quarters
|
|
17
Elevance Health
ELV
$91.1B
| $102M | 1.58% |
361,600
+36,400
| +11% | +$9.9M |
2018 Q2
4 quarters
|
|
18
Bausch Health
BHC
$3.07B
| $94.3M | 1.46% |
3,740,700
| – | – |
2018 Q3
3 quarters
|
|
19
PTC Therapeutics
PTCT
$5.01B
| $94M | 1.46% |
2,089,700
+570,000
| +38% | +$22.5M |
2018 Q3
3 quarters
|
|
20
Inspire Medical Systems
INSP
$1.97B
| $89.2M | 1.38% |
1,471,000
| – | – |
2018 Q2
4 quarters
|
|
|
21
Natera
NTRA
$59.7B
| $88.9M | 1.38% |
3,224,328
+2,146,742
| +199% | +$47.4M |
2015 Q3
15 quarters
|
|
|
LOGC
22
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
| $84.1M | 1.3% |
6,466,783
| – | – |
2018 Q4
2 quarters
|
|
23
Exelixis
EXEL
$17.2B
| $83.6M | 1.3% |
3,912,900
+1,111,000
| +40% | +$23.3M |
2018 Q2
4 quarters
|
|
|
AVDR
24
DELISTED
Avedro, Inc Common Stock
AVDR
| $83.3M | 1.29% |
4,240,128
| – | – |
2019 Q1
1 quarter
|
|
25
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $81.6M | 1.26% |
3,618,171
| – | – |
2017 Q3
7 quarters
|
|
Similar funds
OrbiMed's Q2 2019 Portfolio in Review
As of Q2 2019, OrbiMed held 145 positions worth $6.46B, down 0.04% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
OrbiMed's Q2 2019 filing shows 22 new, 28 increased, 21 reduced and 17 closed positions. Its largest new stake was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M. The largest sale was Clementia Pharmaceuticals Inc., an estimated $272M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.
- OrbiMed's largest Q2 2019 buy was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M.
- OrbiMed added most to Natera in Q2 2019, an estimated $47.4M increase.
- OrbiMed's biggest Q2 2019 reduction was Viatris, cutting an estimated $77.1M.
- OrbiMed fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $272M.
- OrbiMed's ten largest holdings make up 39% of its $6.46B portfolio in Q2 2019.
- OrbiMed opened 22 new positions and closed 17 in Q2 2019.
- OrbiMed's portfolio value fell 0.04% quarter-over-quarter to $6.46B.
Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.